Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.64 |
| ▸ | EYA2 | O00167 | 1/20 | 0.64 |
| ▸ | APP | P05067 | 1/20 | 0.64 |
| ▸ | ACE | P12821 | 1/20 | 0.64 |
| ▸ | BLM | P54132 | 2/20 | 0.61 |
| ▸ | PMP22 | Q01453 | 2/20 | 0.61 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.61 |
| ▸ | LMNA | P02545 | 1/20 | 0.61 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.61 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.61 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.61 |
| ▸ | TSHR | P16473 | 1/20 | 0.61 |
| ▸ | DRD1 | P21728 | 1/20 | 0.61 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.61 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.61 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.61 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.61 |
| ▸ | DRD3 | P35462 | 1/20 | 0.61 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.61 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Edetic Acid SCHEMBL1077971 | 0.93 | TDP1 (0.61) | TDP1EYA2APPACEBLM | |
| SCHEMBL700291 | 0.91 | TDP1 (0.62) | TDP1EYA2APPACEBLM | |
| SCHEMBL27092853 | 0.91 | TDP1 (0.52) | TDP1EYA2APPACEBLM | |
| SCHEMBL111010 | 0.91 | TDP1 (0.56) | TDP1EYA2APPACEBLM | |
| Edetic Acid SCHEMBL8590091 | 0.91 | TDP1 (0.70) | TDP1EYA2APPACEBLM | |
| SCHEMBL11797447 | 0.89 | TDP1 (0.54) | TDP1EYA2APPACEBLM | |
| SCHEMBL22053950 | 0.89 | TDP1 (0.58) | TDP1EYA2APPACEBLM | |
| SCHEMBL13060101 | 0.89 | TDP1 (0.58) | TDP1EYA2APPACEBLM | |
| Edetic Acid SCHEMBL1933513 | 0.88 | TDP1 (0.54) | TDP1EYA2APPACEBLM | |
| SCHEMBL29223010 | 0.88 | TDP1 (0.54) | TDP1EYA2APPACEBLM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7615566-B2 | Substituted pyrrolidine and related compounds | THERAVANCE, INC. (US) | 2009-11-10 | — | — | US | disclosed |
| US-20080161577-A1 | Substituted pyrrolidine and related compounds | THERAVANCE BIOPHARMA R&D IP, LLC | 2008-07-03 | — | — | US | disclosed |
| US-20080146649-A1 | Substituted pyrrolidine and related compounds | THERAVANCE BIOPHARMA R&D IP, LLC | 2008-06-19 | — | — | US | disclosed |
| US-7351717-B2 | Substituted pyrrolidine and related compounds | THERAVANCE, INC. (US) | 2008-04-01 | — | — | US | disclosed |
| US-20070135482-A1 | Substituted pyrrolidine and related compounds | THERAVANCE BIOPHARMA R&D IP, LLC | 2007-06-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070135482-A1 | Substituted pyrrolidine and related compounds | CHRM1, CHRM5, CHRM2 | TDP1 2309/4885EYA2 2942/4885APP 1235/4885 |
| US-20080161577-A1 | Substituted pyrrolidine and related compounds | CHRM1, CHRM5, CHRM2 | TDP1 2309/4885EYA2 2942/4885APP 1235/4885 |
| US-20080146649-A1 | Substituted pyrrolidine and related compounds | CHRM1, CHRM5, CHRM2 | TDP1 2309/4885EYA2 2942/4885APP 1235/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.